Gut check: new study probes how hepatitis drug changes your microbiome

NCT ID NCT07429864

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The goal is to better understand why some patients respond to treatment and others don't.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROBIAL COLONIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile acid malabsorption, primary, 1 cirrhosis of liver Dysbiosis fibrotic liver disease hepatitis B virus infection hepatitis C virus infection hepatitis D virus infection hepatocellular carcinoma HIV infectious disease idiopathic malabsorption due to bile acid synthesis defects infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione Policlinico Universitaro A. Gemelli IRCSS UOC CEMAD

    RECRUITING

    Roma, 00168, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••